GI Oncology

Advertisement
Katy MarshallUnresectable HCC | June 21, 2024
Patients then received 35 to 50 Gy of SBRT in 5 fractions, followed by an identical imaging process while waiting for a DDLT.
Read More
Emily MenendezGastroesophageal Cancer | June 21, 2024
Claudin 18 isoform 2 is an emerging therapeutic target in gastric and gastroesophageal cancers.
Emily MenendezGEP-NETs | June 20, 2024
First-line 177Lu-Dotatate with octreotide LAR can extend median PFS by 14 months in patients with advanced GEP-NETs.
Katy MarshallPancreatic Cancer | June 20, 2024
The chimeric antigen receptor-modified T-cell therapy CT041 singles out claudin18.2 in solid tumors.
Katy MarshallColorectal Cancer | June 18, 2024
In patients with mismatch repair-deficient colorectal cancer, PD-1 blockade has demonstrated positive benefits.
Shikha Jain, MD, FACPColorectal Cancer | June 18, 2024
The panel concludes with the challenges of implementing cutting-edge research into colorectal cancer care and practice.
Shikha Jain, MD, FACPColorectal Cancer | June 18, 2024
The panel explores sequencing challenges for therapies like fruquintinib, TAS-102, and sotorasib for colorectal cancer.
Shikha Jain, MD, FACPColorectal Cancer | June 18, 2024
The panel expands on the incorporation of ctDNA in the CRC adjuvant setting, highlighting its prognostic value.
Shikha Jain, MD, FACPColorectal Cancer | June 18, 2024
The panel details strategies for managing oligometastatic CRC, emphasizing the importance of a multidisciplinary approach.
Shikha Jain, MD, FACPColorectal Cancer | June 18, 2024
The panel swaps opinions on advancements in EGFR and KRAS inhibitors, as well as the importance of NGS and liquid biopsy.
Shikha Jain, MD, FACPColorectal Cancer | June 18, 2024
The panel focuses on the evolution of CRC treatment paradigms, including advances in chemo, biologic agents, and more.
Kai-Keen Shiu, MD, PhDColorectal Cancer | June 18, 2024
Kai-Keen Shiu, MD, PhD, continues his discussion on neoadjuvant pembrolizumab for patients with colorectal cancer.
Kai-Keen Shiu, MD, PhDColorectal Cancer | June 18, 2024
Dr. Shiu also discusses how the NEOPRISM-CRC study exceeded its primary endpoint with a high pCR rate.
Erica Barnell, MD, PhDColorectal Cancer | June 15, 2024
Dr. Barnell gives an update on the FDA approval of ColoSense and how the test can aid in public health initiatives.
Emily MenendezGastroesophageal Cancer | June 13, 2024
qFME with oral administration of bevacizumab-800CW and cetuximab-800CW is feasible, and can shorten procedure time.
Emily MenendezGIST | June 13, 2024
NeoBOMB1 can be used in the theranostic setting for wtGIST when no effective standard of care treatment is available.
Johnathan Ebben, MD, PhDBile Duct Cancer | June 12, 2024
Drs. Ebben and Uboha break down the importance of the QUIC study, a phase 2 investigation of first-line treatment of BTC.
Zachary BessetteLiver Cancer | June 11, 2024
Integrated PET/MRI may be superior to PET/CT in diagnosing malignant tumor liver metastasis/lymphoma hepatic infiltration.
Brandon TwyfordHepatocellular Carcinoma | June 11, 2024
[68Ga]Ga-RYZ-GPC3 shows high specificity in detecting hepatocellular carcinoma, outperforming conventional imaging.
Cathy Eng, MD, FACP, FASCOGastroesophageal Cancer | June 11, 2024
Dr. Eng opines on how the ESOPEC study will alter the treatment paradigm for patients with esophageal/GEJ adenocarcinoma.
Advertisement
Advertisement
Advertisement
Latest News

June 21, 2024